Abstract
Coronavirus disease 2019 (COVID-19), the disease responsible for the devastating pandemic that began at the end of 2019, has been associated with a significantly increased risk of pulmonary thrombosis, even in patients receiving prophylactic anticoagulation. The presence of pulmonary thrombosis may explain why hypoxemia is out of proportion to impairment in lung compliance in some patients with COVID-19 pneumonia. Because pulmonary embolism and COVID-19 pneumonia share many signs and symptoms, diagnosing pulmonary embolism in patients with COVID-19 can be challenging. Given the high mortality and morbidity associated with severe COVID-19, and the concern that aspects of the disease may be driven by thrombosis, many hospital systems have instituted aggressive anticoagulation protocols above standard venous thromboembolism prophylaxis. In this review, the epidemiology, pathophysiology, diagnosis, and treatment of PE in COVID-19 are discussed.
Original language | English |
---|---|
Title of host publication | Pulmonary Embolism |
Publisher | Springer International Publishing |
Pages | 249-258 |
Number of pages | 10 |
ISBN (Electronic) | 9783030870904 |
ISBN (Print) | 9783030870898 |
DOIs | |
State | Published - 1 Jan 2021 |
Keywords
- Anticoagulation
- COVID-19
- Immunothrombosis
- Pulmonary embolism
- Thrombosis